Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
Roivant Sciences (ROIV) Stock Price & Analysis
461 Followers
ROIV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.25 - $13.24
Previous Close$11
Volume4.05M
Average Volume (3M)4.94M
Market Cap
$8.13B
Enterprise Value$2.57B
Total Cash (Recent Filing)$6.54B
Total Debt (Recent Filing)$499.75M
Price to Earnings (P/E)2.2
Beta0.92
Next Earnings
Aug 12, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.07
Shares Outstanding738,721,807
10 Day Avg. Volume5,469,388
30 Day Avg. Volume4,937,144
Standard Deviation0.22
R-Squared0.14
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.33
Price to Sales (P/S)237.37
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.45
Enterprise Value/Gross Profit23.53
Enterprise Value/Ebitda0.60
Forecast
1Y Price Target
$18.67Price Target Upside69.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Roivant Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentBrepocitinib met all primary and secondary endpoints in the Phase 2 PoC study for active non-infectious uveitis.
Debt RestructuringDebt restructuring of Vtama significantly reduces the amount of capital required for Dermavant to achieve profitability.
Market PotentialThe price target for ROIV shares has been raised from $13 to $17, reflecting increased confidence in brepocitinib's market potential.
Bears Say
Product AdoptionVtama is not gaining broad adoption in psoriasis.
Regulatory And Commercial RisksThere remain regulatory and commercial uncertainties limiting the value of the pipeline asset.
Sales PerformanceROIV ended FY4Q23 with $19.3M Vtama sales, below Visible Alpha consensus and GS estimates, largely due to a reduction in GTN, which it attributed to a single contract.
---
Ownership Overview
71.06% Insiders
9.30% Mutual Funds
7.93% Other Institutional Investors
11.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $8.24 and its highest was $13.24 in the past 12 months.
What is Roivant Sciences’s market cap?
Currently, no data Available
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Aug 12, 2024 which is in 21 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on May 30, 2024. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.264 by $0.074.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -$0.24.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 738,721,800 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.264. Following the earnings report the stock price went down -3.169%.
Which hedge fund is a major shareholder of Roivant Sciences?
Among the largest hedge funds holding Roivant Sciences’s share is Viking Global Investors LP. It holds Roivant Sciences’s shares valued at 731M.
---
Roivant Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (69.73% Upside)
$18.67 (69.73% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.67%
12-Months-Change
Fundamentals
Return on Equity
122.05%
Trailing 12-Months
Asset Growth
202.25%
Trailing 12-Months
Company Description
Roivant Sciences
Montes Archimedes Acquisition Corp is a blank check company.
---
ROIV Company Deck
---
ROIV Earnings Call
Q4 2024
0:00 / 0:00
---
ROIV Stock 12 Month Forecast
Average Price Target
$18.67
▲(69.73% Upside)
Technical Analysis
Best Analysts Covering ROIV
1 Year
1 Year Success Rate
10/11 ratings generated profit
1 Year Average Return
+39.07%
reiterated a buy rating 4 months ago
Copying Robyn Karnauskas's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +39.07% per trade.
---